Treatment-naive patients were randomly assigned ( 2:1 ratio ) by an interactive voice-response system with a computer-generated random allocation sequence ( stratified by cirrhosis status ) to receive daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily or placebo for 12 weeks .